•
China-based CanSino Biologics Inc. (HKG: 6185) has entered into a collaboration agreement with Saudi pharmaceutical firm SPIMACO, a leader in the Middle East and North Africa (MENA) region. The partnership aims to enhance access to CanSino’s ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4, trade name: Menhycia) in Saudi Arabia and other…
•
Chinese firms CanSino Biologics Inc. (HKG: 6185) and Grand Life Sciences have entered into an agreement to commercialize CanSino’s adsorbed tetanus vaccine. Under the terms of the deal, Grand Life Sciences will exclusively promote the product in Greater China upon its marketing approval. CanSino Biologics will receive an upfront payment,…
•
China-based vaccine specialist CanSino Biologics Inc. (HKG: 6185) announced that its absorbed diphtheria, tetanus, acellular pertussis (DTcP), Haemophilus influenzae type b (Hib), and Group ACYW135 meningococcal (MCV4) combined vaccine has received clinical trial approval from the National Medical Products Administration (NMPA). The single-dose vaccine aims to provide comprehensive immune protection…
•
China-based vaccines specialist CanSino Biologics Inc. (HKG: 6185) announced that the New Drug Application (NDA) for its DTcP vaccine for infants and young children (under 2 years old), which was accepted for review by the National Medical Products Administration (NMPA) in December of last year, is now under priority review.…
•
China-based vaccines specialist CanSino Biotechnology Inc. (HKG: 6185) announced that the National Medical Products Administration (NMPA) has accepted a New Drug Application (NDA) for its adsorbed tetanus vaccine for review. The vaccine is indicated for the prevention of non-neonatal tetanus. This acceptance marks a significant milestone in the development and…
•
China-based CanSino Biologics (HKG: 6185) has received market approval from the Badan Pengawas Obat dan Makanan (BPOM) of Indonesia for its ACYW135 Meningococcal Conjugate Vaccine (CRM197), commercially known as Menhycia. Menhycia: Protection for Infants and Young ChildrenMenhycia is indicated for infants and young children aged between 3 months to 3…
•
CanSino Biologics (SHA: 688185, HKG: 6185) has announced the initiation of a Phase I/II study for its CS-2036, a recombinant polio vaccine, in Indonesia with financial support from the Bill & Melinda Gates Foundation. This development is accompanied by the first subject enrollment in the Phase I trial. Additionally, the…
•
China-based vaccines specialist CanSino Biologics Inc. (HKG: 6185) has announced that the National Medical Products Administration (NMPA) has accepted for review a New Drug Application (NDA) for its DTcP vaccine, designed for infants and young children under the age of 2. Quality Consistency and Market GapThe DTcP vaccine, a component…
•
China-based CanSino Biologics (SHA: 688185, HKG: 6185) has entered into a strategic partnership with Indonesia-based PT Etana Biotechnologies (Etana) to focus on the research and development of inhaled tuberculosis vaccines. The collaboration aims to leverage both companies’ expertise to advance novel vaccination methods against tuberculosis, although no financial details of…
•
CanSino Biologics (HKG: 6185) has announced that the National Medical Products Administration (NMPA) has accepted its supplementary market filing for the ACYW135 Meningococcal Conjugate Vaccine (CRM197), trade named Menhycia. The Chinese biotechnology company is looking to extend the vaccine’s approved age range to include children from 3 months to 6…
•
China-based biopharmaceutical company CanSino Biologics (HKG: 6185) has announced the commencement of a Phase I clinical study for its freeze-dried Haemophilus influenzae type b (Hib) conjugate vaccine, marking a significant step in the development of this important pediatric vaccine. The study has begun with the enrollment of the first subject,…
•
The Bill & Melinda Gates Foundation has committed USD 17 million to support the development of CS-2036, a recombinant polio vaccine, by China-based CanSino Biologics (SHA: 688185, HKG: 6185). The investment will fund various development efforts, including clinical trials, process development, scaling-up, and the development of a candidate combined vaccine…
•
CanSino Biologics Inc. (HKG: 6185), a leading Chinese biotechnology company, has entered into a strategic partnership with the National Institute of Biotechnology Malaysia (NIBM). The collaboration aims to enhance the development, manufacturing, technology transfer, and talent exchange between the two entities, focusing on mRNA multivalent influenza vaccines and the exploration…
•
China-based biopharmaceutical company CanSino Biologics (HKG: 6185) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its freeze-dried Haemophilus influenzae type B (Hib) conjugate vaccine. Haemophilus influenzae, a Gram-negative bacterium, is a leading cause of acute lower respiratory tract infections in children.…
•
CanSino Biologics (HKG: 6185), a leading Chinese biopharmaceutical company, has released its financial report for 2023, recording revenues of RMB 345.2 million (USD 47.7 million), a decrease of 67% year-on-year (YOY). This decline is primarily attributed to the reduced demand for COVID-19 vaccines, resulting in a RMB 253.2 million refund.…
•
China-based CanSino Biologics (HKG: 6185) has announced the launch of a Phase III clinical study for its ACYW135 Meningococcal Conjugate Vaccine (CRM197), branded as Menhycia, in Indonesia, with the first subject already enrolled. This pivotal study aims to evaluate both the safety and immunogenicity of the vaccine in individuals aged…
•
CanSino Biologics Inc., (HKG: 6185), a leading vaccine specialist based in China, has entered into a strategic partnership with Asymchem Laboratories (Tianjin) Co., Ltd (SHE: 002821), a Contract Development and Manufacturing Organization (CDMO). This collaboration is designed to drive the development of cutting-edge technologies that align with market demands. The…
•
CanSino Biologics Inc., (HKG: 6185), a leading Chinese biopharmaceutical company, has announced that the National Medical Products Administration (NMPA) has accepted for review the New Drug Application (NDA) for its CRM197, a 13-valent pneumococcal polysaccharide conjugate vaccine (TT vector). This development marks a significant step forward in the advancement of…
•
CanSino Biologics (SHA: 688185, HKG: 6185), a China-based biotechnology firm, has announced the enrollment of its first patient in a Phase I clinical study for its recombinant polio vaccine in Australia. This candidate vaccine is a non-infectious virus-like particle (VLP) formulation, developed utilizing CanSino’s proprietary protein structure design and VLP…
•
A wave of Chinese pharmaceutical companies has announced the receipt of Emergency Use Authorizations (EUAs) for their COVID-19 vaccines targeting the Omicron XBB variant. Among the notable developments are Lizhu Pharmaceutical’s (HKG: 1513) recombinant bivalent vaccine, which combines the prototype strain with the Omicron XBB variant, and CanSino Biologics’ (SHA:…